Feb 15, 2023 / 09:20PM GMT
Christopher Liu - SVB Securities LLC - Analyst
Good afternoon, everyone, and welcome to the SVB Global Biopharma Conference. My name is Christopher Liu, and I'm an analyst here at SVB Securities. We're very happy to be hosting Nurix Therapeutics here with their CEO, Arthur Sands, as well as the CFO, Hans van Houte.
Before we get started, I would just like to say that if you have any questions, you can feel free to e-mail them to me directly at [email protected] or use the platform directly to input your questions. And now to just jump right in, I guess. For those new to the story, could you guys provide us a short overview for the company?
Arthur Sands - Nurix Therapeutics, Inc. - President, CEO, and Board Director
Certainly. And before I get started, I should mention we will be making certain forward-looking statements. So I refer you to our filings with the SEC regarding risk factors. So we are focused on targeted protein modulation drugs. We invent new drugs that work via this new mechanism of action of altering protein levels within
Nurix Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 16, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers